Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, announced today that new data from two Phase 2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE